Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 135.41
CLDX's Cash to Debt is ranked higher than
53% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CLDX: 135.41 )
Ranked among companies with meaningful Cash to Debt only.
CLDX' s 10-Year Cash to Debt Range
Min: 2.73  Med: 106.39 Max: No Debt
Current: 135.41
Equity to Asset 0.92
CLDX's Equity to Asset is ranked higher than
88% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CLDX: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
CLDX' s 10-Year Equity to Asset Range
Min: -0.32  Med: 0.83 Max: 0.94
Current: 0.92
-0.32
0.94
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
94% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 43.23
M-Score: -1.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3334.87
CLDX's Operating margin (%) is ranked lower than
86% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CLDX: -3334.87 )
Ranked among companies with meaningful Operating margin (%) only.
CLDX' s 10-Year Operating margin (%) Range
Min: -3414.11  Med: -628.78 Max: -13.79
Current: -3334.87
-3414.11
-13.79
Net-margin (%) -3237.20
CLDX's Net-margin (%) is ranked lower than
86% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CLDX: -3237.20 )
Ranked among companies with meaningful Net-margin (%) only.
CLDX' s 10-Year Net-margin (%) Range
Min: -3292.81  Med: -658.55 Max: -5.41
Current: -3237.2
-3292.81
-5.41
ROE (%) -42.77
CLDX's ROE (%) is ranked lower than
60% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CLDX: -42.77 )
Ranked among companies with meaningful ROE (%) only.
CLDX' s 10-Year ROE (%) Range
Min: -2929.64  Med: -62.23 Max: -3.4
Current: -42.77
-2929.64
-3.4
ROA (%) -38.33
CLDX's ROA (%) is ranked lower than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CLDX: -38.33 )
Ranked among companies with meaningful ROA (%) only.
CLDX' s 10-Year ROA (%) Range
Min: -319.26  Med: -42.55 Max: -2.02
Current: -38.33
-319.26
-2.02
ROC (Joel Greenblatt) (%) -1117.73
CLDX's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CLDX: -1117.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4720  Med: -611.49 Max: -10.72
Current: -1117.73
-4720
-10.72
Revenue Growth (3Y)(%) -44.20
CLDX's Revenue Growth (3Y)(%) is ranked lower than
81% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CLDX: -44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -67.6  Med: -23.80 Max: 105.3
Current: -44.2
-67.6
105.3
EBITDA Growth (3Y)(%) 9.30
CLDX's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CLDX: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.2  Med: -3.20 Max: 22.6
Current: 9.3
-32.2
22.6
EPS Growth (3Y)(%) 5.30
CLDX's EPS Growth (3Y)(%) is ranked higher than
63% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CLDX: 5.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.6  Med: -6.90 Max: 133.6
Current: 5.3
-64.6
133.6
» CLDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CLDX Guru Trades in Q2 2014

Columbia Wanger 3,583,600 sh (+34.12%)
Murray Stahl 26,335 sh (unchged)
» More
Q3 2014

CLDX Guru Trades in Q3 2014

First Eagle Investment 250,000 sh (New)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 3,571,600 sh (-0.33%)
» More
Q4 2014

CLDX Guru Trades in Q4 2014

First Eagle Investment 559,542 sh (+123.82%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 3,196,700 sh (-10.50%)
» More
Q1 2015

CLDX Guru Trades in Q1 2015

Joel Greenblatt 35,223 sh (New)
Paul Tudor Jones 28,309 sh (New)
Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
Columbia Wanger 2,800,700 sh (-12.39%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.98
CLDX's P/B is ranked lower than
62% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CLDX: 5.98 )
Ranked among companies with meaningful P/B only.
CLDX' s 10-Year P/B Range
Min: 1.25  Med: 5.15 Max: 50.74
Current: 5.98
1.25
50.74
P/S 580.46
CLDX's P/S is ranked lower than
95% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CLDX: 580.46 )
Ranked among companies with meaningful P/S only.
CLDX' s 10-Year P/S Range
Min: 1.68  Med: 24.64 Max: 1268
Current: 580.46
1.68
1268
Current Ratio 17.22
CLDX's Current Ratio is ranked higher than
88% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CLDX: 17.22 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s 10-Year Current Ratio Range
Min: 0.56  Med: 6.39 Max: 17.22
Current: 17.22
0.56
17.22
Quick Ratio 17.22
CLDX's Quick Ratio is ranked higher than
89% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CLDX: 17.22 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s 10-Year Quick Ratio Range
Min: 0.56  Med: 6.39 Max: 17.22
Current: 17.22
0.56
17.22
Days Sales Outstanding 67.79
CLDX's Days Sales Outstanding is ranked lower than
56% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CLDX: 67.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s 10-Year Days Sales Outstanding Range
Min: 1.43  Med: 43.44 Max: 132.73
Current: 67.79
1.43
132.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.12
CLDX's Price/Net Cash is ranked higher than
56% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. CLDX: 7.12 )
Ranked among companies with meaningful Price/Net Cash only.
CLDX' s 10-Year Price/Net Cash Range
Min: 2.75  Med: 7.67 Max: 47.3
Current: 7.12
2.75
47.3
Price/Net Current Asset Value 7.03
CLDX's Price/Net Current Asset Value is ranked higher than
52% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CLDX: 7.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDX' s 10-Year Price/Net Current Asset Value Range
Min: 2.62  Med: 6.90 Max: 1163
Current: 7.03
2.62
1163
Price/Tangible Book 6.77
CLDX's Price/Tangible Book is ranked lower than
56% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CLDX: 6.77 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDX' s 10-Year Price/Tangible Book Range
Min: 2.07  Med: 6.23 Max: 55.86
Current: 6.77
2.07
55.86
Price/Median PS Value 19.27
CLDX's Price/Median PS Value is ranked lower than
98% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CLDX: 19.27 )
Ranked among companies with meaningful Price/Median PS Value only.
CLDX' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 1.26 Max: 48.06
Current: 19.27
0.07
48.06
Earnings Yield (Greenblatt) (%) -6.34
CLDX's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CLDX: -6.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.6  Med: 391.85 Max: 436.8
Current: -6.34
-6.6
436.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
comment on CLDX Mar 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference Jul 02 2015
Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference Jul 02 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer Jul 01 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer Jul 01 2015
Celldex Cancer Vaccine May Get Fast-Tracked Jul 01 2015
Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog Jun 30 2015
Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of... Jun 29 2015
Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of... Jun 29 2015
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jun 11 2015
Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind Jun 05 2015
Celldex Glioblastoma Vaccine Hits Phase II Primary Endpoint - Analyst Blog Jun 02 2015
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate Jun 02 2015
An Immunotherapy To Treat Brain Cancer Rises In The Wake Of A Public Loss Jun 02 2015
Celldex vaccine helps brain cancer patients live longer -study May 31 2015
Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma... May 31 2015
ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients May 31 2015
Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma... May 31 2015
Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK